Literature DB >> 32514992

Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease.

Adi Nitzan-Luques1,2, Mordechai Slae1,3, Diaa Zugayar4, Bradley P Dixon5, Karen Meir6, Oded Volovelsky7,8.   

Abstract

Neonatal thrombotic microangiopathy (TMA) is a rare and severe disease characterized by a triad of non-immune hemolytic anemia, thrombocytopenia, and organ dysfunction in neonates. We describe herein an early-term infant who underwent hemicolectomy at 4 days of age due to intestinal perforation. Following surgery, the patient had recurrent bouts of vomiting and abdominal distention, together with acute kidney injury, non-immune hemolytic anemia, and severe thrombocytopenia. Low complement levels raised the possibility of complement-mediated neonatal TMA. Finally, genetic tests identified a heterozygous mutation in the complement factor I gene. Anti-C5 monoclonal antibody therapy led to complete cessation of the hematological and renal manifestations, but symptoms of intestinal obstruction recurred. Intestinal biopsy demonstrated aganglionosis, compatible with Hirschsprung disease. This presentation is the first known case of neonatal complement-mediated TMA associated with Hirschsprung disease. Moreover, it highlights the importance of considering a diagnosis of TMA in cases of atypical neonatal infectious presentation.

Entities:  

Keywords:  Atypical hemolytic uremic syndrome; Complement; Factor I; Pediatric nephrology; Thrombotic microangiopathies

Year:  2020        PMID: 32514992     DOI: 10.1007/s40620-020-00766-5

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  19 in total

1.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 2.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

Review 3.  Haemolytic uraemic syndrome.

Authors:  Fadi Fakhouri; Julien Zuber; Véronique Frémeaux-Bacchi; Chantal Loirat
Journal:  Lancet       Date:  2017-02-25       Impact factor: 79.321

4.  A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.

Authors:  Sara C Nilsson; Diana Karpman; Fariba Vaziri-Sani; Ann-Charlotte Kristoffersson; Rémi Salomon; Francois Provot; Veronique Fremeaux-Bacchi; Leendert A Trouw; Anna M Blom
Journal:  Mol Immunol       Date:  2006-11-07       Impact factor: 4.407

5.  Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.

Authors:  Marie-Agnès Dragon-Durey; Véronique Frémeaux-Bacchi; Chantal Loirat; Jacques Blouin; Patrick Niaudet; Georges Deschenes; Paul Coppo; Wolf Herman Fridman; Laurence Weiss
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

Review 6.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

7.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Authors:  Timothy H J Goodship; H Terence Cook; Fadi Fakhouri; Fernando C Fervenza; Véronique Frémeaux-Bacchi; David Kavanagh; Carla M Nester; Marina Noris; Matthew C Pickering; Santiago Rodríguez de Córdoba; Lubka T Roumenina; Sanjeev Sethi; Richard J H Smith
Journal:  Kidney Int       Date:  2016-12-16       Impact factor: 10.612

8.  Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics.

Authors:  Lianne M Geerdink; Dineke Westra; Joanna A E van Wijk; Eiske M Dorresteijn; Marc R Lilien; Jean-Claude Davin; Martin Kömhoff; Koen Van Hoeck; Amerins van der Vlugt; Lambertus P van den Heuvel; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2012-03-13       Impact factor: 3.714

9.  An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy.

Authors:  Christof Aigner; Alice Schmidt; Martina Gaggl; Gere Sunder-Plassmann
Journal:  Clin Kidney J       Date:  2019-04-21

10.  Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy in first degree relatives: a case report.

Authors:  Thomas Idorn; Lone Schejbel; Casper Rydahl; James Goya Heaf; Karen Riis Jølvig; Marie Bergstrøm; Peter Garred; Anne-Lise Kamper
Journal:  BMC Nephrol       Date:  2012-07-26       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.